Recent Recurrent Ovarian Cancer News

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed,... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy.... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (July 13, 2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United... Continue Reading

Drug Rucaparib Promising in Pretreated BRCA-Positive Ovarian Cancer (June 15, 2015)

The drug rucaparib appears active in women with recurrent BRCA-positive ovarian cancer that has progressed after previous treatment. These findings were presented at 2015 Annual Meeting of the American... Continue Reading

Lynparza Approved in Advanced Ovarian Cancer (December 29, 2014)

CancerConnect News: The U.S. Food and Drug Administration has granted accelerated approval to LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective... Continue Reading

Avastin Approved by the FDA for Recurrent Ovarian Cancer (December 2, 2014)

The FDA approval was based on the results of the AURELIA clinical trial, which involved 361 women with ovarian cancer that had recurred less than 6 months after their most recent platinum-based chemotherapy... Continue Reading

AFCR Scientists Uncovered Potential New Treatment for Ovarian Cancer (November 11, 2014)

(CancerConnect) A potential new treatment for ovarian cancer – the most lethal cancer of the female reproductive system – has recently been uncovered, thanks to research supported in part by the... Continue Reading

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer (October 21, 2014)

The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results... Continue Reading

Next Page »